Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...

Research and development expenses were $37.9 million for the quarter ended June 30, 2025, compared to $14.1 million for the same period in 2024. The increase of $23.8 million was primarily driven by ...

Kashiv BioSciences, LLC and MS Pharma today announced that the companies have entered into a license and supply agreement for ...

Intervention/Treatment: The trial tests Itepekimab, administered subcutaneously in high and low doses, alongside Mometasone furoate nasal spray. The purpose is to improve symptoms in patients with ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

GSK's six-monthly IL-5 inhibitor depemokimab clears two phase 3 trials in chronic rhinosinusitis with nasal polyps (CRSwNP), its second indication.

Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in ...

Our upcoming readouts in CRSwNP and severe asthma represent key program milestones and an opportunity to further demonstrate the potentially unique profile of TSLP receptor inhibition across multiple ...

Therapeutic blockade of the TSLP ligand is a well-validated approach that has demonstrated clinically meaningful efficacy in asthma, chronic obstructive pulmonary disease (COPD), and chronic ...